2022
PET/CT radiomics potentially improves progression-free survival (PFS) and overall survival (OS) prognostication beyond UICC TNM staging in oropharyngeal squamous cell carcinoma (OPSCC) patients
Haider S, Sharaf K, Zeevi T, Mahajan A, Forghani R, Judson B, Kann B, Burtness B, Reichel C, Baumeister P, Payabvash S. PET/CT radiomics potentially improves progression-free survival (PFS) and overall survival (OS) prognostication beyond UICC TNM staging in oropharyngeal squamous cell carcinoma (OPSCC) patients. Laryngo-Rhino-Otologie 2022, 101: s184-s184. DOI: 10.1055/s-0042-1746471.Peer-Reviewed Original Research
2016
Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)
Cohen E, Licitra L, Burtness B, Fayette J, Gauler T, Clement P, Grau J, del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Cong X, Gibson N, Solca F, Ehrnrooth E, Machiels J. Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1). International Journal Of Radiation Oncology • Biology • Physics 2016, 94: 868-869. DOI: 10.1016/j.ijrobp.2015.12.032.Peer-Reviewed Original Research
2015
Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
Cohen E, Licitra L, Fayette J, Gauler T, Clement P, Grau J, Del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Dupuis N, Burtness B, Gibson N, Solca F, Ehrnrooth E, Machiels J. Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). Journal Of Clinical Oncology 2015, 33: 6023-6023. DOI: 10.1200/jco.2015.33.15_suppl.6023.Peer-Reviewed Original Research